{"type": "root", "children": [{"type": "p", "children": [{"type": "t", "text": "\nRecent studies have identified miR-1293 as a tumor‐suppressive microRNA in various cancer contexts. Functional screening has revealed that miR-1293 can simultaneously target oncogenic regulators such as BRD4 and key DNA repair factors including APEX1, RPA1, and POLD4, thereby impairing tumor cell growth and synergistically enhancing the efficacy of anticancer therapies in preclinical models."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "1"}]}, {"type": "t", "text": "\n"}]}, {"type": "t", "text": "\n\n"}, {"type": "p", "children": [{"type": "t", "text": "\nIn renal malignancies, miR-1293 has also emerged as a promising prognostic biomarker. Bioinformatic analyses in papillary renal cell carcinoma have associated its expression profile with patient outcomes, while focused studies in renal cell carcinoma indicate that elevated miR-1293 levels correlate with increased tumor cell viability, migration, and invasion through the direct suppression of hydrocyanic oxidase 2 (HAO2). This dual observation suggests that miR-1293 may exert context-dependent roles by acting as a biomarker in one setting and contributing to tumor progression in another."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "2"}]}, {"type": "t", "text": "\n"}]}, {"type": "t", "text": "\n\n"}, {"type": "p", "children": [{"type": "t", "text": "\nFurther extending its clinical relevance, studies in osteosarcoma have demonstrated that cisplatin treatment induces the upregulation of miR-1293 via promoter hypomethylation, which disrupts transcriptional repression by TFAP2A. The consequent increase in miR-1293 levels leads to the targeting and suppression of TIMP1, thereby inactivating the Notch1/Hes1 and TGFBR1/Smad2/3 signaling pathways, promoting tumor cell apoptosis and enhancing chemosensitivity. These findings highlight the potential of miR-1293 not only as a therapeutic target but also as a modulator of chemotherapy response in osteosarcoma."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "4"}]}, {"type": "t", "text": "\n"}]}, {"type": "rg", "children": [{"type": "r", "ref": 1, "children": [{"type": "t", "text": "Yuki Takagawa, Yasuyuki Gen, Tomoki Muramatsu, et al. "}, {"type": "b", "children": [{"type": "t", "text": "miR-1293, a Candidate for miRNA-Based Cancer Therapeutics, Simultaneously Targets BRD4 and the DNA Repair Pathway."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Mol Ther (2020)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1016/j.ymthe.2020.04.001"}], "href": "https://doi.org/10.1016/j.ymthe.2020.04.001"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "32320642"}], "href": "https://pubmed.ncbi.nlm.nih.gov/32320642"}]}, {"type": "r", "ref": 2, "children": [{"type": "t", "text": "Wen Luo, Lei Wang, Mao-Hua Luo, et al. "}, {"type": "b", "children": [{"type": "t", "text": "hsa-mir-3199-2 and hsa-mir-1293 as Novel Prognostic Biomarkers of Papillary Renal Cell Carcinoma by COX Ratio Risk Regression Model Screening."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "J Cell Biochem (2017)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1002/jcb.26008"}], "href": "https://doi.org/10.1002/jcb.26008"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "28338236"}], "href": "https://pubmed.ncbi.nlm.nih.gov/28338236"}]}, {"type": "r", "ref": 3, "children": [{"type": "t", "text": "Xiao-Li Liu, Wen-Gu Pan, Kai-Lin Li, et al. "}, {"type": "b", "children": [{"type": "t", "text": "miR-1293 Suppresses Tumor Malignancy by Targeting Hydrocyanic Oxidase 2: Therapeutic Potential of a miR-1293/Hydrocyanic Oxidase 2 Axis in Renal Cell Carcinoma."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Cancer Biother Radiopharm (2020)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1089/cbr.2019.2957"}], "href": "https://doi.org/10.1089/cbr.2019.2957"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "31971830"}], "href": "https://pubmed.ncbi.nlm.nih.gov/31971830"}]}, {"type": "r", "ref": 4, "children": [{"type": "t", "text": "Tingxuan Wang, Jincheng Huang, Gang Chen, et al. "}, {"type": "b", "children": [{"type": "t", "text": "miR-1293 suppresses osteosarcoma progression by modulating drug sensitivity in response to cisplatin treatment."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Int Immunopharmacol (2024)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1016/j.intimp.2024.111702"}], "href": "https://doi.org/10.1016/j.intimp.2024.111702"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "38367464"}], "href": "https://pubmed.ncbi.nlm.nih.gov/38367464"}]}]}]}